{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:41:31Z","timestamp":1762674091488},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0146222","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T20:30:38Z","timestamp":1453321838000},"page":"e0146222","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy"],"prefix":"10.1371","volume":"11","clinical-trial-number":[{"clinical-trial-number":"ctri\/2010\/091\/000107","registry":"10.18810\/clinical-trial-registry-india"}],"author":[{"given":"Alka","family":"Deshpande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Toshniwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendrakumar H.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"ref1","article-title":"The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients","volume":"Volume 2009","author":"Jussi Sutinen","journal-title":"PPAR Research"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-010-0152-1","article-title":"Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection","volume":"13","author":"JG Troll","year":"2011","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2012.06.063","article-title":"HIV and coronary heart disease: time for a better understanding","volume":"61","author":"F Boccara","year":"2013","journal-title":"J AM Coll Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00006454-200301000-00018","article-title":"Metabolic complications of antiretroviral therapy in children","volume":"22","author":"EG Leonard","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"ref5","first-page":"561","article-title":"Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV","volume":"93","author":"AS Kramer","year":"2009","journal-title":"Arq Bras Cardiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-010-0152-1","article-title":"Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection","volume":"13","author":"JG Troll","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00041433-200402000-00011","article-title":"Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'","volume":"15","author":"A Balasubramanyam","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"ref8","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominant PPAR\u03b1 agonist and moderate \u03b3 agonist activity in healthy human subjects","author":"RH Jani","year":"2013","journal-title":"Clin Drug Investigation"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)","volume":"16","author":"RH Jani","year":"2014","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"V Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1468-1293.2007.00480.x","article-title":"The management of dyslipidemias in Antiretroviral-treated HIV Infection: A Systematic Review","volume":"8","author":"C McGoldrick","year":"2007","journal-title":"HIV Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(98)00022-1","article-title":"Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities","volume":"352","author":"K Henry","year":"1998","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1468-1293.2004.00200.x","article-title":"Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999\u20132001","volume":"5","author":"F Bonnet","year":"2004","journal-title":"HIV Med."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00126334-200210010-00018","article-title":"Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy","volume":"31","author":"R Palacios","year":"2002","journal-title":"J Acquir. Immune Defic Syndr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2003.10.006","article-title":"Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults","volume":"172","author":"S Badiou","year":"2004","journal-title":"Atherosclerosis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/S1413-86702001000600007","article-title":"Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate","volume":"5","author":"B Caramelli","year":"2001","journal-title":"Braz J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00002030-199905070-00023","article-title":"Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients","volume":"13","author":"RG Hewitt","year":"1999","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/00002030-200211080-00012","article-title":"A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia","volume":"16","author":"J Miller","year":"2002","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000441-200406000-00003","article-title":"Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy","volume":"327","author":"Rao A","year":"2004","journal-title":"Am J Med Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/jinf.2001.0829","article-title":"Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate","volume":"42","author":"R Manfredi","year":"2001","journal-title":"J Infect"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s15010-001-2052-3","article-title":"Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART","volume":"30","author":"L Calza","year":"2002","journal-title":"Infection"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"H Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/17460875.3.2.175","article-title":"Current and future treatments of HIV-associated dyslipidemia","volume":"3","author":"MT Bennett","year":"2008","journal-title":"Future Lipidology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/aid.2005.21.757","article-title":"A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087","volume":"21","author":"JA Aberg","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association Conference on Scientific Issues Related to Definition","volume":"109","author":"SM Grundy","year":"2004","journal-title":"Circulation"},{"key":"ref26","first-page":"000","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"00","author":"SC Smith Jr","year":"2013","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1874192401105010049","article-title":"HIV and HAART-Associated Dyslipidemia","volume":"5","author":"RF Eoin","year":"2011","journal-title":"The Open Cardiovascular Medicine Journal"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2337\/dc07-0358","article-title":"Insulin Sensitivity and Insulin Secretion Determined by Homeostasis Model Assessment (HOMA) and Risk of Diabetes in a Multiethnic Cohort of Women: The Women\u2019s Health InitiativeObservational Study","volume":"30","author":"S Yiqing","year":"2007","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"E490","DOI":"10.1152\/ajpendo.00118.2003","article-title":"Alterations in lipid kinetics in men with HIV-dyslipidemia","volume":"285","author":"DN Reeds","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00126334-200103010-00004","article-title":"Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy","volume":"26","author":"M Schmitz","year":"2001","journal-title":"J Acq Immune Defic Syndr"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1210\/jc.2004-1273","article-title":"Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodefi ciency virusinfected patients with mild dyslipidemia","volume":"90","author":"M Shahmanesh","year":"2005","journal-title":"J Clin EndocrinolMetab"},{"key":"ref32","first-page":"415","article-title":"Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy","volume":"15","author":"L Baril","year":"2001","journal-title":"AIDS(London, England)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individualstreated with protease inhibitors. The Swiss HIV Cohort Study","volume":"100","author":"D Periard","year":"1999","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2007.09.042","article-title":"Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy","volume":"198","author":"E Anuurad","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1046\/j.1525-1497.2002.20201.x","article-title":"Evaluation and management of dyslipidemia in patient with HIV","volume":"17","author":"LG Michael","year":"2002","journal-title":"J Gen Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0146222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T21:31:05Z","timestamp":1567546265000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0146222"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0146222","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}